409
Participants
Start Date
October 12, 2019
Primary Completion Date
May 8, 2021
Study Completion Date
May 8, 2021
99mTc-3PRGD2 injection
A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
Peking University Cancer Hospital & Institute, Beijing
Peking Union Medical College Hospital, Beijing
Shengjing Hospital of China Medical University, Shengyang
China-Japan Union Hospital of Jilin University, Changchun
Renji Hospital of Shanghai Jiao Tong University, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
West China Hospital of Sichuan University, Chengdu
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot
First Hospital of Shanxi Medical Universit, Taiyuan
Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.
INDUSTRY
RDO Pharm.
INDUSTRY